Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia

被引:50
作者
Orlandi, Ester M. [1 ]
Rocca, Barbara [1 ]
Pazzano, Anna S. [2 ]
Ghio, Stefano [2 ]
机构
[1] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, I-27100 Pavia, Italy
[2] Fdn IRCCS Policlin San Matteo, Cardiac Thorac & Vasc Dept, I-27100 Pavia, Italy
关键词
CHRONIC-PHASE; PLEURAL EFFUSION; BCR-ABL; IMATINIB; FAILURE; PATIENT;
D O I
10.1016/j.leukres.2011.08.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:E4 / E6
页数:3
相关论文
共 10 条
[1]   Guidelines for the diagnosis and treatment of pulmonary hypertension [J].
Galie, N. ;
Hoeper, M. M. ;
Humbert, M. ;
Torbicki, A. ;
Vachiery, J-L. ;
Barbera, J. A. ;
Beghetti, M. ;
Corris, P. ;
Gaine, S. ;
Gibbs, J. S. ;
Gomez-Sanchez, M. A. ;
Jondeau, G. ;
Klepetko, W. ;
Opitz, C. ;
Peacock, A. ;
Rubin, L. ;
Zellweger, M. ;
Simonneau, G. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (06) :1219-1263
[2]   Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy [J].
Ghofrani, Hossein A. ;
Morrell, Nicholas W. ;
Hoeper, Marius M. ;
Olschewski, Horst ;
Peacock, Andrew J. ;
Barst, Robyn J. ;
Shapiro, Shelley ;
Golpon, Heiko ;
Toshner, Mark ;
Grimminger, Friedrich ;
Pascoe, Steve .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (09) :1171-1177
[3]   Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? [J].
Hennigs, Jan K. ;
Keller, Gunhild ;
Baumann, Hans Joerg ;
Honecker, Friedemann ;
Kluge, Stefan ;
Bokemeyer, Carsten ;
Bruemmendorf, Tim H. ;
Klose, Hans .
BMC PULMONARY MEDICINE, 2011, 11
[4]   Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].
Kantarjian, Hagop ;
Shah, Neil P. ;
Hochhaus, Andreas ;
Cortes, Jorge ;
Shah, Sandip ;
Ayala, Manuel ;
Moiraghi, Beatriz ;
Shen, Zhixiang ;
Mayer, Jiri ;
Pasquini, Ricardo ;
Nakamae, Hirohisa ;
Huguet, Francoise ;
Boque, Concepcion ;
Chuah, Charles ;
Bleickardt, Eric ;
Bradley-Garelik, M. Brigid ;
Zhu, Chao ;
Szatrowski, Ted ;
Shapiro, David ;
Baccarani, Michele .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270
[5]   Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient [J].
Mattei, D. ;
Feola, M. ;
Orzan, F. ;
Mordini, N. ;
Rapezzi, D. ;
Gallamini, A. .
BONE MARROW TRANSPLANTATION, 2009, 43 (12) :967-968
[6]   Dasatinib 100 mg Once Daily Minimizes the Occurrence of Pleural Effusion in Patients With Chronic Myeloid Leukemia in Chronic Phase and Efficacy Is Unaffected in Patients who Develop Pleural Effusion [J].
Porkka, Kimmo ;
Khoury, H. Jean ;
Paquette, Ronald L. ;
Matloub, Yousif ;
Sinha, Ritwik ;
Cortes, Jorge E. .
CANCER, 2010, 116 (02) :377-386
[7]  
Quintas-Cardama A, 2007, J CLIN ONCOL, V25, P3908, DOI 10.1200/JCO.2007.12.0329
[8]   Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia [J].
Rasheed, Walid ;
Flaim, Brendan ;
Seymour, John F. .
LEUKEMIA RESEARCH, 2009, 33 (06) :861-864
[9]   Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets [J].
Rix, Uwe ;
Hantschel, Oliver ;
Duernberger, Gerhard ;
Rix, Lily L. Remsing ;
Planyavsky, Melanie ;
Fernbach, Nora V. ;
Kaupe, Ines ;
Bennett, Keiryn L. ;
Valent, Peter ;
Colinge, Jacques ;
Kocher, Thomas ;
Superti-Furga, Giulio .
BLOOD, 2007, 110 (12) :4055-4063
[10]   Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib [J].
Shah, Neil P. ;
Kim, Dong-Wook ;
Kantarjian, Hagop ;
Rousselot, Philippe ;
Dorlhiac Llacer, Pedro Enrique ;
Enrico, Alicia ;
Vela-Ojeda, Jorge ;
Silver, Richard T. ;
Khoury, Hanna Jean ;
Mueller, Martin C. ;
Lambert, Alexandre ;
Matloub, Yousif ;
Hochhaus, Andreas .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02) :232-240